Our top pick for
BIO-key International, Inc is a security & protection services business based in the US. BIO-key International shares (BKYI) are listed on the NASDAQ and all prices are listed in US Dollars. BIO-key International employs 34 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$2.75 - $9.52|
|50-day moving average||$3.52|
|200-day moving average||$3.72|
|Wall St. target price||$6.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.56|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$2.8 million|
|Gross profit TTM||$2 million|
|Return on assets TTM||-26%|
|Return on equity TTM||-107.19%|
|Market capitalisation||$27.4 million|
TTM: trailing 12 months
There are currently 809,623 BIO-key International shares held short by investors – that's known as BIO-key International's "short interest". This figure is 20.2% down from 1.0 million last month.
There are a few different ways that this level of interest in shorting BIO-key International shares can be evaluated.
BIO-key International's "short interest ratio" (SIR) is the quantity of BIO-key International shares currently shorted divided by the average quantity of BIO-key International shares traded daily (recently around 490680.60606061). BIO-key International's SIR currently stands at 1.65. In other words for every 100,000 BIO-key International shares traded daily on the market, roughly 1650 shares are currently held short.
However BIO-key International's short interest can also be evaluated against the total number of BIO-key International shares, or, against the total number of tradable BIO-key International shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BIO-key International's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 BIO-key International shares in existence, roughly 100 shares are currently held short) or 0.1123% of the tradable shares (for every 100,000 tradable BIO-key International shares, roughly 112 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BIO-key International.
Find out more about how you can short BIO-key International stock.
We're not expecting BIO-key International to pay a dividend over the next 12 months.
BIO-key International's shares were split on a 1:8 basis on 19 November 2020. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BIO-key International shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for BIO-key International shares which in turn could have impacted BIO-key International's share price.
Over the last 12 months, BIO-key International's shares have ranged in value from as little as $2.75 up to $9.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BIO-key International's is 1.0061. This would suggest that BIO-key International's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
BIO-key International, Inc. , together with its subsidiaries, develops and markets fingerprint identification biometric technology, enterprise-ready identity access management solutions, and software solutions to commercial, government, and education customers in the United States and internationally. The company offers BIO-key PortalGuard and PortalGuard IDaaS solutions, a customer-controlled and neutral-by-design cloud-based identity platform that allows customers to integrate with any cloud or on-premise SaaS application, as well as windows device authentication through IAM platform. Its solutions enable its customers to secure their workforces and student populations; and make their partner networks more collaborative. In addition, it provides BIO-key VST and WEB-key products; and Civil and Large-Scale ID Infrastructure solutions develops finger-based biometric technology. Further, it offers finger scanners for enterprise and consumer markets under SideSwipe, EcoID, and SidePass brand names. The company was formerly known as SAC Technologies and changed its name to BIO-key International, Inc.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.